News

19 December 2017 / Club News

2018 WADA Prohibited List of substances

To: Secretaries/Chief Executive Officers of Unions and Regional Associations
in Membership of World Rugby
From: David Carrigy
Head of Development & International Relations
Date: December 14, 2017
Re: 2018 WADA Prohibited List
Please find attached the 2018 WADA Prohibited List of substances and methods
prohibited in sport and applicable to Rugby effective from January 1, 2018.
Also attached are the following supporting documents:
a) 2018 Explanatory Notes (outlines the modifications from the 2017 Prohibited List
to the 2018 Prohibited List)
b) 2018 Monitoring Programme (Outlines the substances placed on WADA’s
monitoring programme)
The 2018 Prohibited List and the supporting documents are also available for download
and reference on the WADA website www.wada-ama.org, and will also be made
available on World Rugby’s anti-doping website under the Resources tab
www.keeprugbyclean.com.
Please forward these documents to all your relevant rugby constituents, medical
representatives and those involved in anti-doping within your Union.
If you have any queries regarding the WADA 2018 Prohibited List, please contact the
World Rugby Anti-Doping Manager – Compliance & Results, David Ho, at
david.ho@worldrugby.org or +353 1 2409 209.
Yours sincerely,
David Carrigy
Head of Development & International Relations
THE WORLD ANTI-DOPING CODE
INTERNATIONAL
STANDARD
PROHIBITED LIST
JANUARY 2018
The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French.
In the event of any conflict between the English and French versions, the English version shall prevail.
This List shall come into effect on 1 January 2018
2
IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL
BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND
PROHIBITED METHODS M1, M2 AND M3.
PROHIBITED SUBSTANCES
SUBSTANCES & METHODS
PROHIBITED AT ALL TIMES
(IN- AND OUT-OF-COMPETITION)
NON-APPROVED SUBSTANCES
Any pharmacological substance which is not
addressed by any of the subsequent sections of the
List and with no current approval by any governmental
regulatory health authority for human therapeutic use
(e.g. drugs under pre-clinical or clinical development
or discontinued, designer drugs, substances approved
only for veterinary use) is prohibited at all times.
ANABOLIC AGENTS
Anabolic agents are prohibited.
1. ANABOLIC ANDROGENIC STEROIDS (AAS)
a. Exogenous* AAS, including:
1-Androstenediol (5α-androst-1-ene-3β,17β-diol);
1-Androstenedione (5α-androst-1-ene-3,17-dione);
1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one);
1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one);
4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-
one);
Bolandiol (estr-4-ene-3β,17β-diol);
Bolasterone;
Calusterone;
Clostebol;
Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-
17α-methylandrosta-1,4-dien-3-one);
Desoxymethyltestosterone (17α-methyl-5α-androst-
2-en-17β-ol);
Drostanolone;
Ethylestrenol (19-norpregna-4-en-17α-ol);
Fluoxymesterone;
Formebolone;
Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-
androstan-17β-ol);
Gestrinone;
S0
S1
Mestanolone;
Mesterolone;
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-
3-one);
Metenolone;
Methandriol;
Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-
androstan-3-one);
Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-
3-one);
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-
androst-1-en-3-one);
Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-
3-one);
Methyltestosterone;
Metribolone (methyltrienolone, 17β-hydroxy-17α-
methylestra-4,9,11-trien-3-one);
Mibolerone;
Norboletone;
Norclostebol;
Norethandrolone;
Oxabolone;
Oxandrolone;
Oxymesterone;
Oxymetholone;
Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'Hpyrazolo[
3,4:2,3]-5α-androstane);
Quinbolone;
Stanozolol;
Stenbolone;
Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-
pregna-4,9,11-trien-3-one);
Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);
and other substances with a similar chemical structure
or similar biological effect(s).
3
b. Endogenous** AAS when administered exogenously:
19-Norandrostenediol (estr-4-ene-3,17-diol);
19-Norandrostenedione (estr-4-ene-3,17-dione);
Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-
androstan-3-one);
Androstenediol (androst-5-ene-3β,17β-diol);
Androstenedione (androst-4-ene-3,17-dione);
Boldenone;
Boldione (androsta-1,4-diene-3,17-dione);
Nandrolone (19-nortestosterone);
Prasterone (dehydroepiandrosterone, DHEA,
3β-hydroxyandrost-5-en-17-one);
Testosterone;
and their metabolites and isomers, including but
not limited to:
3β-Hydroxy-5α-androstan-17-one;
5α-Androst-2-ene-17-one;
5α-Androstane-3α,17α-diol;
5α-Androstane-3α,17β-diol;
5α-Androstane-3β,17α-diol;
5α-Androstane-3β,17β-diol;
5β-Androstane-3α,17β-diol;
7α-Hydroxy-DHEA;
7β-Hydroxy-DHEA;
4-Androstenediol (androst-4-ene-3β, 17β-diol);
5-Androstenedione (androst-5-ene-3,17-dione);
7-Keto-DHEA;
19-Norandrosterone;
19-Noretiocholanolone;
Androst-4-ene-3α,17α-diol;
Androst-4-ene-3α,17β-diol;
Androst-4-ene-3β,17α-diol;
Androst-5-ene-3α,17α-diol;
Androst-5-ene-3α,17β-diol;
Androst-5-ene-3β,17α-diol;
Androsterone;
Epi-dihydrotestosterone;
Epitestosterone;
Etiocholanolone.
2. OTHER ANABOLIC AGENTS
Including, but not limited to:
Clenbuterol, selective androgen receptor modulators
(SARMs, e.g. andarine, LGD-4033, ostarine and RAD140),
tibolone, zeranol and zilpaterol.
For purposes of this section:
* “ exogenous” refers to a substance which is not ordinarily
produced by the body naturally.
** “ endogenous” refers to a substance which is ordinarily produced
by the body naturally.
PEPTIDE HORMONES, GROWTH FACTORS,
RELATED SUBSTANCES, AND MIMETICS
The following substances, and other substances with
similar chemical structure or similar biological effect(s),
are prohibited:
1. Erythropoietins (EPO) and agents affecting erythropoiesis,
including, but not limited to:
1.1 Erythropoietin-Receptor Agonists, e.g.
Darbepoetins (dEPO);
Erythropoietins (EPO);
EPO based constructs [EPO-Fc, methoxy polyethylene
glycol-epoetin beta (CERA)];
EPO-mimetic agents and their constructs
(e.g. CNTO-530, peginesatide).
1.2 Hypoxia-inducible factor (HIF) activating agents, e.g.
Argon;
Cobalt;
Molidustat;
Roxadustat (FG-4592);
Xenon.
1.3 GATA inhibitors, e.g.
K-11706.
1.4 TGF-beta (TGF-β) inhibitors, e.g.
Luspatercept;
Sotatercept.
S2
4
1.5 Innate repair receptor agonists, e.g.
Asialo EPO;
Carbamylated EPO (CEPO).
2. Peptide Hormones and Hormone Modulators,
2.1 Chorionic Gonadotrophin (CG) and Luteinizing
Hormone (LH) and their releasing factors, e.g.
Buserelin, deslorelin, gonadorelin, goserelin,
leuprorelin, nafarelin and triptorelin, in males;
2.2 Corticotrophins and their releasing factors, e.g.
Corticorelin;
2.3 Growth Hormone (GH), its fragments and releasing
factors, including, but not limited to:
Growth Hormone fragments, e.g.
AOD-9604 and hGH 176-191;
Growth Hormone Releasing Hormone (GHRH) and
its analogues, e.g.
CJC-1293, CJC-1295, sermorelin and tesamorelin;
Growth Hormone Secretagogues (GHS), e.g.
ghrelin and ghrelin mimetics, e.g.
anamorelin, ipamorelin and tabimorelin;
GH-Releasing Peptides (GHRPs), e.g.
alexamorelin, GHRP-1, GHRP-2 (pralmorelin),
GHRP-3, GHRP-4, GHRP-5, GHRP-6, and hexarelin.
3. Growth Factors and Growth Factor Modulators,
including, but not limited to:
Fibroblast Growth Factors (FGFs);
Hepatocyte Growth Factor (HGF);
Insulin-like Growth Factor-1 (IGF-1) and its analogues;
Mechano Growth Factors (MGFs);
Platelet-Derived Growth Factor (PDGF);
Thymosin-β4 and its derivatives e.g. TB-500;
Vascular-Endothelial Growth Factor (VEGF).
Additional growth factors or growth factor modulators
affecting muscle, tendon or ligament protein synthesis/
degradation, vascularisation, energy utilization,
regenerative capacity or fibre type switching.
BETA-2 AGONISTS
All selective and non-selective beta-2 agonists,
including all optical isomers, are prohibited.
Including, but not limited to:
Fenoterol;
Formoterol;
Higenamine;
Indacaterol;
Olodaterol;
Procaterol;
Reproterol;
Salbutamol;
Salmeterol;
Terbutaline;
Tulobuterol;
Vilanterol.
Except:
• Inhaled salbutamol: maximum 1600 micrograms over
24 hours in divided doses not to exceed 800 micrograms
over 12 hours starting from any dose;
• Inhaled formoterol: maximum delivered dose of
54 micrograms over 24 hours;
• Inhaled salmeterol: maximum 200 micrograms over
24 hours.
The presence in urine of salbutamol in excess of 1000 ng/mL
or formoterol in excess of 40 ng/mL is not consistent with
therapeutic use of the substance and will be considered as an
Adverse Analytical Finding (AAF) unless the Athlete proves,
through a controlled pharmacokinetic study, that the
abnormal result was the consequence of a therapeutic dose
(by inhalation) up to the maximum dose indicated above.
HORMONE AND METABOLIC
MODULATORS
The following hormone and metabolic modulators
are prohibited:
1. Aromatase inhibitors including, but not limited to:
4-Androstene-3,6,17 trione (6-oxo);
Aminoglutethimide;
Anastrozole;
Androsta-1,4,6-triene-3,17-dione (androstatrienedione);
S3
S4
5
Androsta-3,5-diene-7,17-dione (arimistane);
Exemestane;
Formestane;
Letrozole;
Testolactone.
2. Selective estrogen receptor modulators (SERMs)
including, but not limited to:
Raloxifene;
Tamoxifen;
Toremifene.
3. Other anti-estrogenic substances including, but not
limited to:
Clomifene;
Cyclofenil;
Fulvestrant.
4. Agents modifying myostatin function(s) including, but
not limited, to: myostatin inhibitors.
5. Metabolic modulators:
5.1 Activators of the AMP-activated protein kinase
(AMPK), e.g. AICAR, SR9009; and Peroxisome
Proliferator Activated Receptor δ (PPARδ) agonists,
e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)
phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid
(GW1516, GW501516);
5.2 Insulins and insulin-mimetics;
5.3 Meldonium;
5.4 Trimetazidine.
DIURETICS AND MASKING AGENTS
The following diuretics and masking agents are
prohibited, as are other substances with a similar chemical
structure or similar biological effect(s).
Including, but not limited to:
• Desmopressin; probenecid; plasma expanders,
e.g. intravenous administration of albumin, dextran,
hydroxyethyl starch and mannitol.
• Acetazolamide; amiloride; bumetanide; canrenone;
chlortalidone; etacrynic acid; furosemide; indapamide;
metolazone; spironolactone; thiazides, e.g. bendroflumethiazide,
chlorothiazide and hydrochlorothiazide;
triamterene and vaptans, e.g. tolvaptan.
S5
Except:
• Drospirenone; pamabrom; and ophthalmic use of
carbonic anhydrase inhibitors (e.g. dorzolamide,
brinzolamide);
• Local administration of felypressin in dental
anaesthesia.
The detection in an Athlete’s Sample at all times or
In-Competition, as applicable, of any quantity of
the following substances subject to threshold
limits: formoterol, salbutamol, cathine, ephedrine,
methylephedrine and pseudoephedrine, in conjunction
with a diuretic or masking agent, will be considered as
an Adverse Analytical Finding (AAF) unless the Athlete
has an approved Therapeutic Use Exemption (TUE) for
that substance in addition to the one granted for the
diuretic or masking agent.
6
PROHIBITED METHODS
MANIPULATION OF BLOOD AND
BLOOD COMPONENTS
The following are prohibited:
1. The Administration or reintroduction of any quantity of
autologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into the
circulatory system.
2. Artificially enhancing the uptake, transport or delivery
of oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13) and modified
haemoglobin products, e.g. haemoglobin-based blood
substitutes and microencapsulated haemoglobin
products, excluding supplemental oxygen by inhalation.
3. Any form of intravascular manipulation of the blood or
blood components by physical or chemical means.
CHEMICAL AND PHYSICAL
MANIPULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the
integrity and validity of Samples collected during
Doping Control.
Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.
2. Intravenous infusions and/or injections of more than
a total of 100 mL per 12 hour period except for those
legitimately received in the course of hospital
treatments, surgical procedures or clinical diagnostic
investigations.
M1
M2
GENE DOPING
The following, with the potential to enhance sport
performance, are prohibited:
1. The use of polymers of nucleic acids or nucleic acid
analogues.
2. The use of gene editing agents designed to alter genome
sequences and/or the transcriptional or epigenetic
regulation of gene expression.
3. The use of normal or genetically modified cells.
M3
7
IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES
ARE PROHIBITED IN-COMPETITION:
SUBSTANCES & METHODS
PROHIBITED IN-COMPETITION
PROHIBITED SUBSTANCES
STIMULANTS
All stimulants, including all optical isomers, e.g.
d- and l- where relevant, are prohibited.
Stimulants include:
a: Non-Specified Stimulants:
Adrafinil;
Amfepramone;
Amfetamine;
Amfetaminil;
Amiphenazole;
Benfluorex;
Benzylpiperazine;
Bromantan;
Clobenzorex;
Cocaine;
Cropropamide;
Crotetamide;
Fencamine;
Fenetylline;
Fenfluramine;
Fenproporex;
Fonturacetam [4-phenylpiracetam (carphedon)];
Furfenorex;
Lisdexamfetamine;
Mefenorex;
Mephentermine;
Mesocarb;
Metamfetamine(d-);
p-methylamphetamine;
Modafinil;
Norfenfluramine;
Phendimetrazine;
Phentermine;
Prenylamine;
Prolintane.
A stimulant not expressly listed in this section
is a Specified Substance.
S6 b: Specified Stimulants.
Including, but not limited to:
1,3-Dimethylbutylamine;
4-Methylhexan-2-amine (methylhexaneamine);
Benzfetamine;
Cathine**;
Cathinone and its analogues, e.g. mephedrone,
methedrone, and α - pyrrolidinovalerophenone;
Dimethylamphetamine;
Ephedrine***;
Epinephrine**** (adrenaline);
Etamivan;
Etilamfetamine;
Etilefrine;
Famprofazone;
Fenbutrazate;
Fencamfamin;
Heptaminol;
Hydroxyamfetamine (parahydroxyamphetamine);
Isometheptene;
Levmetamfetamine;
Meclofenoxate;
Methylenedioxymethamphetamine;
Methylephedrine***;
Methylphenidate;
Nikethamide;
Norfenefrine;
Octopamine;
Oxilofrine (methylsynephrine);
Pemoline;
Pentetrazol;
Phenethylamine and its derivatives;
Phenmetrazine;
Phenpromethamine;
Propylhexedrine;
Pseudoephedrine*****;
8
Selegiline;
Sibutramine;
Strychnine;
Tenamfetamine (methylenedioxyamphetamine);
Tuaminoheptane;
and other substances with a similar chemical structure
or similar biological effect(s).
Except:
• Clonidine;
• Imidazole derivatives for topical/ophthalmic use
and those stimulants included in the 2018
Monitoring Program*.
* Bupropion, caffeine, nicotine, phenylephrine,
phenylpropanolamine, pipradrol, and synephrine: These
substances are included in the 2018 Monitoring Program, and
are not considered Prohibited Substances.
** Cathine: Prohibited when its concentration in urine is greater
than 5 micrograms per milliliter.
*** Ephedrine and methylephedrine: Prohibited when the
concentration of either in urine is greater than 10 micrograms
per milliliter.
**** Epinephrine (adrenaline): Not prohibited in local administration,
e.g. nasal, ophthalmologic, or co-administration with local
anaesthetic agents.
***** Pseudoephedrine: Prohibited when its concentration in urine
is greater than 150 micrograms per milliliter.
NARCOTICS
The following narcotics are prohibited:
Buprenorphine;
Dextromoramide;
Diamorphine (heroin);
Fentanyl and its derivatives;
Hydromorphone;
Methadone;
Morphine;
Nicomorphine;
Oxycodone;
Oxymorphone;
Pentazocine;
Pethidine.
CANNABINOIDS
The following cannabinoids are prohibited:
• Natural cannabinoids, e.g. cannabis, hashish and
marijuana,
• Synthetic cannabinoids e.g. Δ9-tetrahydrocannabinol
(THC) and other cannabimimetics.
Except:
• Cannabidiol.
GLUCOCORTICOIDS
All glucocorticoids are prohibited when administered
by oral, intravenous, intramuscular or rectal routes.
Including but not limited to:
Betamethasone;
Budesonide;
Cortisone;
Deflazacort;
Dexamethasone;
Fluticasone;
Hydrocortisone;
Methylprednisolone;
Prednisolone;
Prednisone;
Triamcinolone.
S7
S8
S9
9
SUBSTANCES PROHIBITED
IN PARTICULAR SPORTS
BETA-BLOCKERS
Beta-blockers are prohibited In-Competition only, in
the following sports, and also prohibited Out-of-Competition
where indicated.
• Archery (WA)*
• Automobile (FIA)
• Billiards (all disciplines) (WCBS)
• Darts (WDF)
• Golf (IGF)
• Shooting (ISSF, IPC)*
• Skiing/Snowboarding (FIS) in ski jumping, freestyle
aerials/halfpipe and snowboard halfpipe/big air
• Underwater sports (CMAS) in constant-weight apnoea
with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea,
spearfishing, static apnoea, target shooting, and variable
weight apnoea.
*Also prohibited Out-of-Competition
Including, but not limited to:
Acebutolol; Labetalol;
Alprenolol; Levobunolol;
Atenolol; Metipranolol;
Betaxolol; Metoprolol;
Bisoprolol; Nadolol;
Bunolol; Oxprenolol;
Carteolol; Pindolol;
Carvedilol; Propranolol;
Celiprolol; Sotalol;
Esmolol; Timolol.
P1
www.wada-ama.org
1
Prohibited Substances
ANABOLIC AGENTS
• Dihydrotestosterone was renamed to its International
Non-proprietary Name (INN) (androstanolone).
1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one)
was added in S1.a as an example of exogenous
anabolic steroid.
• LGD-4033 and RAD140 were added as further examples
of SARMs.
PEPTIDE HORMONES, GROWTH
FACTORS, RELATED SUBSTANCES
AND MIMETICS
• For clarity and accuracy Section S2 was reorganized.
• ARA290 was removed as an example in this section
because current literature suggests it does not meet
inclusion criteria.
• Deslorelin, goserelin, nafarelin and triptorelin were
added as examples of 2.1.
• Growth Hormone fragments were included in 2.3 with
AOD-9604 and hGH 176-191 added as examples;
CJC-1293 was added as example of GHRH and
tabimorelin as a further example of GH secretagogue.
GHRP-1, -3, -4, and -5 were added as examples
of GHRP.
• Thymosin- β4 and its derivatives, e. g. TB-500, were
added as example of prohibited growth factors.
• Cobalt: It is re-iterated that vitamin B12, which contains
cobalt, is not prohibited.
S1
S2
BETA-2-AGONISTS
• Dosing parameters of salbutamol were revised to make
it clear that divided doses of salbutamol may not exceed
800 micrograms over any 12 hours (see figure).
Inhaled salbutamol – max. 1600 mcg over 24 hours
But not to exceed 800 mcg over any 12 hours
0 12 24
200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg
• Tulobuterol was added as an example.
• The statement on the urinary thresholds was improved.
HORMONE AND METABOLIC
MODULATORS
• Clomifene is now stated by its INN.
• In the absence of an INN, the IUPAC name of GW1516,
2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)
thiazol-5-yl)methylthio)phenoxy) acetic acid as well as
an alternative name (GW501516) were included.
• SR9009, a Rev-Erb-α agonist, was added as an example
of Activators of the AMP-activated protein kinase (AMPK).
S3
Any 12 hour period: max. 800 mcg
S4
SUMMARY OF MAJOR MODIFICATIONS
AND EXPLANATORY NOTES
2018 PROHIBITED LIST
Substances and methods prohibited at all times
(In- and Out-of-Competition)
2
DIURETICS AND MASKING
AGENTS
• In consideration of the information published in
scientific articles since 2012 that particularly addresses
the ability of glycerol to influence the athlete‘s plasma
volume and parameters of the Athlete Biological
Passport (ABP), the magnitude of glycerol-derived
effects is regarded as minimal. Therefore, glycerol has
been removed from the Prohibited List.
Prohibited Methods
CHEMICAL AND PHYSICAL
MANIPULATION
• M2.2: the permitted volume and timing of intravenous
infusions were changed from infusions of no more than
50 mL per 6-hour period to no more than a total of
100 mL per 12-hour period in order to allow greater
flexibility for the safe administration of non-prohibited
therapeutic substances, for example, iron.
• To reflect medical practice, “hospital admissions” has
been changed to “hospital treatments” and “clinical
investigations” has been clarified as “clinical diagnostic
investigations”.
GENE DOPING
• The definition has been revised to include current and
emerging gene manipulating technologies.
Substances and Methods
Prohibited In-Competition
STIMULANTS
• 1,3-Dimethylbutylamine was added as an example. This
substance can be found in some dietary supplements.
S5
M2
M3
S6
CANNABINOIDS
• The category Cannabimimetics, e.g. “Spice, JWH-018,
JWH-073, HU210” was changed to “synthetic
cannabinoids, e.g. Δ9-tetrahydrocannabinol (THC) and
other cannabimimetics”. The synthetic cannabinoids are
one of the main classes of novel psychoactive
substances that have constantly emerging new drugs
and changing availability. The previous list of examples
continues to be prohibited, but are currently used less
commonly. “Other cannabimimetics” replaced
these examples.
• Cannabidiol is no longer prohibited. Synthetic
cannabidiol is not a cannabimimetic; however,
cannabidiol extracted from cannabis plants may also
contain varying concentrations of THC, which remains
a prohibited substance.
GLUCOCORTICOIDS
• Examples of commonly used glucocorticoids were added
for greater clarity.
S8
S9
3
Substances Prohibited
in Particular Sports
ALCOHOL
• After careful consideration and extensive consultation,
Alcohol was excluded from the Prohibited List. The
intent of this change is not to compromise the integrity
or safety of any sport where alcohol use is a concern,
but rather to endorse a different means of enforcing
bans on alcohol use in these sports. The four
International Federations (IF) affected by this change
have been alerted sufficiently in advance in order to
amend their rules and to put in place protocols to test
for alcohol use and appropriately sanction athletes who
do not abide by the rules of their sport. Control of the
process will allow IF more flexibility in applying rules or
thresholds as they see fit. The National Anti-Doping
Organizations are no longer obliged to conduct tests but
may assist IF and National Federations where appropriate.
BETA BLOCKERS
• For logical consistency, the category known as P2. Beta
Blockers was renamed P1. Beta Blockers.
MONITORING PROGRAM
The following were added to evaluate misuse in sport:
• 2-ethylsulfanyl-1H-benzimidazole (bemitil) in- and
out-of-competition
• Hydrocodone in-competition.
Mitragynine and telmisartan were removed from the
Monitoring Program because the required information
on prevalence was obtained.
P1
P2
The following substances are placed on the 2018 Monitoring Program:
1. Stimulants: In-Competition only: Bupropion, caffeine, nicotine, phenylephrine,
phenylpropanolamine, pipradrol and synephrine.
2. Narcotics: In-Competition only: Codeine, hydrocodone and tramadol.
3. Glucocorticoids: In-Competition (by routes of administration other than oral,
intravenous, intramuscular or rectal) and Out-of-Competition
(all routes of administration).
4. 2-ethylsulfanyl-1Hbenzimidazole
(bemitil): In- and Out-of-Competition.
5. Beta-2-agonists: In- and Out-of-Competition: any combination of beta-2-agonists.
* The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and governments, shall establish a monitoring program
regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.”
THE 2018 MONITORING PROGRAM*

There doesn't appear to be any tagged photos.

Upload and Tag Photos

Comment
You must be signed in to add comments
Comments
|